Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Biogen Inc., liquidity ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Current ratio 2.49 1.94 2.01 1.83 1.70 2.15 2.12 1.84 2.06 2.46 1.73 1.72 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29
Quick ratio 1.76 1.36 1.46 1.34 1.21 1.54 1.50 1.32 1.61 2.00 1.39 1.43 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57
Cash ratio 1.25 0.96 0.95 0.88 0.70 0.91 0.80 0.70 0.94 1.26 0.83 0.92 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Biogen Inc. current ratio deteriorated from Q1 2022 to Q2 2022 but then improved from Q2 2022 to Q3 2022 exceeding Q1 2022 level.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Biogen Inc. quick ratio deteriorated from Q1 2022 to Q2 2022 but then improved from Q2 2022 to Q3 2022 exceeding Q1 2022 level.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Biogen Inc. cash ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.

Current Ratio

Biogen Inc., current ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current assets 9,765,800 9,740,900 7,915,900 7,856,500 7,162,300 7,183,700 6,719,500 6,887,100 7,843,100 8,493,800 8,007,200 8,381,800 8,448,200 7,909,800 8,942,600 7,640,900 8,719,000 7,432,100 10,195,400 7,873,300 7,568,000 7,108,700 6,859,700
Current liabilities 3,926,400 5,018,000 3,946,600 4,298,200 4,211,600 3,347,200 3,165,800 3,742,200 3,804,000 3,447,100 4,638,600 4,863,800 4,432,200 3,210,900 3,148,700 3,295,200 3,174,900 3,152,400 3,152,100 3,368,200 3,448,400 3,379,700 2,992,500
Liquidity Ratio
Current ratio1 2.49 1.94 2.01 1.83 1.70 2.15 2.12 1.84 2.06 2.46 1.73 1.72 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.93 0.84 0.82 0.79 1.01 0.91 0.83 0.84 0.95 0.86 3.14 3.18 1.15 0.89 1.04
Amgen Inc. 1.68 1.53 1.44 1.59 1.64 1.31 1.66 1.81 2.28 2.18 1.59 1.44 2.89 2.89 2.77
Bristol-Myers Squibb Co. 1.42 1.44 1.32 1.52 1.47 1.54 1.56 1.58 1.67 1.47 1.66 1.60 3.83 3.88 1.93
Danaher Corp. 1.78 1.75 1.68 1.43 1.48 2.26 2.05 1.86 2.08 2.20 1.32 5.19 3.43 2.32 2.18
Eli Lilly & Co. 1.13 1.10 1.27 1.23 1.30 1.15 1.42 1.40 1.36 1.22 1.11 1.16 1.17 1.13 1.12
Gilead Sciences Inc. 1.30 1.43 1.48 1.27 1.37 1.36 1.37 1.40 3.25 2.33 3.04 3.10 2.96 3.76 3.62
Johnson & Johnson 1.43 1.42 1.39 1.35 1.34 1.39 1.28 1.21 1.48 1.25 1.31 1.26 1.26 1.33 1.44
Merck & Co. Inc. 1.46 1.39 1.40 1.27 1.31 1.31 1.02 1.02 1.30 1.32 1.11 1.24 1.26 1.21 1.37
Moderna Inc. 2.10 1.99 1.77 1.76 1.35 1.24 1.39 1.43 2.43 17.30 9.29 7.89 7.40 6.77 7.17
Pfizer Inc. 1.59 1.42 1.39 1.40 1.39 1.37 1.48 1.35 1.40 1.42 1.03 0.88 0.90 1.47 1.54
Regeneron Pharmaceuticals Inc. 5.36 5.12 4.76 3.56 3.71 3.57 3.12 3.63 3.89 2.12 4.21 3.67 4.03 3.88 4.58
Thermo Fisher Scientific Inc. 1.74 1.65 1.56 1.50 3.19 2.78 2.53 2.13 2.93 2.62 2.32 1.92 1.80 1.49 1.69

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= 9,765,800 ÷ 3,926,400 = 2.49

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Biogen Inc. current ratio deteriorated from Q1 2022 to Q2 2022 but then improved from Q2 2022 to Q3 2022 exceeding Q1 2022 level.

Quick Ratio

Biogen Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 3,675,600 2,646,600 1,749,300 2,261,400 1,541,800 1,742,000 1,217,500 1,331,200 2,224,800 2,384,900 2,591,300 2,913,700 2,343,900 1,723,400 2,243,200 1,224,600 2,386,700 1,250,200 4,108,000 1,573,800 1,548,100 1,169,500 924,000
Marketable securities 1,235,500 2,151,300 2,002,400 1,541,100 1,413,300 1,308,800 1,320,000 1,278,900 1,355,000 1,942,700 1,269,100 1,562,200 2,093,500 1,228,800 1,665,800 2,313,400 2,041,700 1,974,000 1,808,000 2,115,200 1,960,200 1,723,500 1,956,200
Accounts receivable, net 1,568,800 1,567,600 1,632,000 1,549,400 1,723,000 1,688,000 1,854,300 1,913,800 2,024,900 2,133,600 2,092,600 1,880,500 1,933,500 1,959,600 2,088,900 1,958,500 2,017,300 1,951,000 1,939,200 1,787,000 1,567,500 1,630,200 1,501,500
Due from anti-CD20 therapeutic programs 415,400 435,900 389,400 412,300 400,000 422,200 369,800 413,500 527,200 441,100 511,600 590,200 582,300 557,500 527,100 526,900 508,400 481,900 553,500 532,600 518,000 502,900 324,500
Total quick assets 6,895,300 6,801,400 5,773,100 5,764,200 5,078,100 5,161,000 4,761,600 4,937,400 6,131,900 6,902,300 6,464,600 6,946,600 6,953,200 5,469,300 6,525,000 6,023,400 6,954,100 5,657,100 8,408,700 6,008,600 5,593,800 5,026,100 4,706,200
 
Current liabilities 3,926,400 5,018,000 3,946,600 4,298,200 4,211,600 3,347,200 3,165,800 3,742,200 3,804,000 3,447,100 4,638,600 4,863,800 4,432,200 3,210,900 3,148,700 3,295,200 3,174,900 3,152,400 3,152,100 3,368,200 3,448,400 3,379,700 2,992,500
Liquidity Ratio
Quick ratio1 1.76 1.36 1.46 1.34 1.21 1.54 1.50 1.32 1.61 2.00 1.39 1.43 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.69 0.61 0.56 0.56 0.75 0.65 0.61 0.60 0.68 0.58 2.88 2.91 0.92 0.64 0.78
Amgen Inc. 1.17 0.99 0.90 1.06 1.19 0.86 1.16 1.30 1.65 1.60 1.10 1.01 2.28 2.41 2.37
Bristol-Myers Squibb Co. 0.98 1.07 1.03 1.20 1.16 1.16 1.25 1.28 1.43 1.26 1.38 1.26 3.63 3.61 1.64
Danaher Corp. 1.19 1.13 1.08 0.89 0.93 1.67 1.51 1.36 1.52 1.59 0.92 4.68 2.99 1.78 1.58
Eli Lilly & Co. 0.71 0.67 0.77 0.80 0.79 0.67 0.83 0.85 0.79 0.68 0.64 0.68 0.66 0.67 0.65
Gilead Sciences Inc. 0.96 1.06 1.06 0.95 1.01 1.05 0.99 1.08 2.93 2.09 2.78 2.86 2.74 3.41 3.32
Johnson & Johnson 1.10 1.09 1.06 1.04 1.03 1.04 0.97 0.91 1.17 0.92 0.98 0.94 0.93 0.95 1.01
Merck & Co. Inc. 0.90 0.85 0.84 0.73 0.78 0.75 0.58 0.58 0.77 0.84 0.66 0.78 0.80 0.75 0.88
Moderna Inc. 1.62 1.55 1.44 1.52 1.21 1.13 1.30 1.37 2.35 17.01 9.10 7.74 7.22 6.64 7.01
Pfizer Inc. 1.18 1.02 0.95 1.00 0.99 0.91 0.88 0.78 0.93 0.98 0.60 0.50 0.50 0.71 0.72
Regeneron Pharmaceuticals Inc. 4.37 4.20 3.95 2.98 3.03 2.92 2.39 2.86 3.02 1.61 3.38 2.81 3.14 2.99 3.66
Thermo Fisher Scientific Inc. 1.06 0.98 0.97 1.00 2.37 1.92 1.70 1.63 2.16 1.83 1.48 1.19 0.97 0.85 0.89

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 6,895,300 ÷ 3,926,400 = 1.76

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Biogen Inc. quick ratio deteriorated from Q1 2022 to Q2 2022 but then improved from Q2 2022 to Q3 2022 exceeding Q1 2022 level.

Cash Ratio

Biogen Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Cash and cash equivalents 3,675,600 2,646,600 1,749,300 2,261,400 1,541,800 1,742,000 1,217,500 1,331,200 2,224,800 2,384,900 2,591,300 2,913,700 2,343,900 1,723,400 2,243,200 1,224,600 2,386,700 1,250,200 4,108,000 1,573,800 1,548,100 1,169,500 924,000
Marketable securities 1,235,500 2,151,300 2,002,400 1,541,100 1,413,300 1,308,800 1,320,000 1,278,900 1,355,000 1,942,700 1,269,100 1,562,200 2,093,500 1,228,800 1,665,800 2,313,400 2,041,700 1,974,000 1,808,000 2,115,200 1,960,200 1,723,500 1,956,200
Total cash assets 4,911,100 4,797,900 3,751,700 3,802,500 2,955,100 3,050,800 2,537,500 2,610,100 3,579,800 4,327,600 3,860,400 4,475,900 4,437,400 2,952,200 3,909,000 3,538,000 4,428,400 3,224,200 5,916,000 3,689,000 3,508,300 2,893,000 2,880,200
 
Current liabilities 3,926,400 5,018,000 3,946,600 4,298,200 4,211,600 3,347,200 3,165,800 3,742,200 3,804,000 3,447,100 4,638,600 4,863,800 4,432,200 3,210,900 3,148,700 3,295,200 3,174,900 3,152,400 3,152,100 3,368,200 3,448,400 3,379,700 2,992,500
Liquidity Ratio
Cash ratio1 1.25 0.96 0.95 0.88 0.70 0.91 0.80 0.70 0.94 1.26 0.83 0.92 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.36 0.29 0.23 0.28 0.43 0.30 0.31 0.30 0.33 0.25 2.50 2.56 0.61 0.32 0.38
Amgen Inc. 0.80 0.57 0.51 0.66 0.87 0.55 0.82 0.91 1.24 1.09 0.68 0.69 1.94 2.05 2.07
Bristol-Myers Squibb Co. 0.48 0.63 0.66 0.78 0.73 0.68 0.75 0.83 1.03 0.92 0.95 0.84 3.10 3.02 0.99
Danaher Corp. 0.64 0.53 0.49 0.32 0.35 1.07 0.93 0.82 0.94 0.99 0.52 4.04 2.40 1.08 0.84
Eli Lilly & Co. 0.18 0.18 0.19 0.26 0.28 0.22 0.26 0.29 0.30 0.20 0.14 0.21 0.15 0.20 0.19
Gilead Sciences Inc. 0.54 0.61 0.62 0.56 0.56 0.64 0.58 0.65 2.52 1.79 2.34 2.50 2.39 3.03 2.97
Johnson & Johnson 0.75 0.73 0.70 0.70 0.70 0.65 0.60 0.59 0.79 0.52 0.54 0.54 0.51 0.49 0.53
Merck & Co. Inc. 0.49 0.44 0.40 0.34 0.42 0.39 0.26 0.30 0.36 0.50 0.32 0.47 0.39 0.35 0.47
Moderna Inc. 1.23 1.16 1.09 1.18 0.89 0.90 0.92 1.05 2.22 16.81 9.05 7.71 7.16 6.61 6.97
Pfizer Inc. 0.82 0.70 0.61 0.73 0.71 0.61 0.51 0.47 0.64 0.70 0.31 0.26 0.25 0.40 0.39
Regeneron Pharmaceuticals Inc. 2.44 2.49 2.34 1.45 1.56 1.05 1.09 1.33 1.29 0.85 1.95 1.53 1.63 1.56 2.14
Thermo Fisher Scientific Inc. 0.26 0.17 0.23 0.33 1.55 1.01 0.80 1.00 1.21 0.97 0.54 0.39 0.22 0.30 0.19

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 4,911,100 ÷ 3,926,400 = 1.25

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Biogen Inc. cash ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022.